Background: Artemisinin-based combination therapy (ACT) is the treatment of choice for uncomplicated falciparum malaria. Artemether-lumefantrine (AL), a fixed dose co-formulation, has recently been approved for marketing in India, although it is not included in the National Drug Policy for treatment of malaria. Efficacy of short course regimen (4 × 4 tablets of 20 mg artemether plus 120 mg lumefantrine over 48 h) was demonstrated in India in the year 2000. However, low cure rates in Thailand and better plasma lumefantrine concentration profile with a six-dose regimen over three days, led to the recommendation of higher dose globally. This is the first report on the therapeutic efficacy of the six-dose regimen of AL in Indian uncomplicated falciparum malaria patients. The data generated will help in keeping the alternative ACT ready for use in the National Programme as and when required.
Background
Resistance in Plasmodium falciparum to commonly used anti-malarial drugs, especially chloroquine, is being increasingly recognized in India [1] . More than 80% of the therapeutic efficacy studies (n = 143) conducted from 2001-07 indicate failure to chloroquine beyond cut off level of 10% (unpublished data). WHO recommends use of artemisinin-based combination therapy (ACT) to counter the development of resistance in P. falciparum to antimalarials and to achieve rapid resolution of parasitaemia and morbidity [2] . Accordingly, the National drug policy has been revised in India in favor of using ACT. Although at present artesunate plus sulphadoxine/pyrimethamine (AS+SP) has been recommended for the treatment of uncomplicated falciparum malaria, data are also being generated for new fixed dose combinations to help the National Programme to adopt the most effective, easy to administer, feasible, safe and cost-effective strategy.
Artemether-lumefantrine (AL) is a co-formulation of artemether and lumefantrine (an aryl alcohol related to quinine, mefloquine and halofantrine). The reported 28 day cure rate for six-dose regimen ranges between 89.6 and 98.5% and 42 day cure rate ranges between 87 and 94.8% [3] [4] [5] . In India, 28 day cure rate of 94.5% was reported by Kshirsagar et al [6] with four dose regimen (4 × 4 tablets of 20 mg artemether plus 120 mg lumefantrine over 48 h) in a double-blind comparative study with chloroquine in falciparum malaria. However, in Thailand this regimen resulted in failure rates of 20%, which reduced to 5% by using a six-dose regimen [7] . Therefore, high efficacy observed earlier in South-East Asia (SEA) with low dose, including India, may be due to background immunity which may not be sustainable. In addition, the better plasma lumefantrine concentration profiles have been observed with high dose regimen [8] .
The present study was conducted to evaluate the efficacy of AL with six-dose regimen in two endemic regions of India following the WHO (2003) therapeutic efficacy protocols [9] .
Methods

Study site and design
The study was conducted in Kamrup district (Assam) in north-eastern India and Keonjhar district (Orissa) in eastern part of India (Figure 1 ), where the annual parasite incidence in 2006 were 2.7 and 17.5, respectively. At both the sites, malaria transmission is perennial with the predominance of falciparum malaria (76.3% in Kamrup and 96.5% in Keonjhar).
It was an open label, single arm prospective trial based on the therapeutic efficacy protocols of WHO [9] . The primary end point was 28-day cure rate. Secondary end points included proportion of aparasitaemic patient on days 1, 2 and 3 and post-treatment gametocyte carriage. The study was approved by the Ministry of Health, Govt. of India and the Ethics Committee of National Institute of Malaria Research.
Patients
Patients with microscopically confirmed P. falciparum malaria (asexual parasites 1,000-100,000/μl), with fever (axillary temperarture, ≥ 37.5°C) or history of fever in preceeding 24 h, who gave voluntary consent were enrolled in local clinics. Pregnant or lactating women and children under 5 kg bodyweight were excluded. Patients with other febrile conditions, danger signs [9] or severe malaria were also excluded.
Procedures
After obtaining the informed written consent from patients or guardian, a medical history including presenting symptoms, current medications and previous antimalarial use was obtained. A complete physical examination was performed and case record form was completed for each patient. Clinical history, examination and other investigations were all recorded. Blood was collected for parasitology and molecular biology studies.
Treatment
Patients were given AL (Coartem ® , Novartis Pharmaceuticals Corporation, Suffern, New York, USA; Batch No.: F0443) according to body weight with biscuits and glass of water. Patients weighing 10-15 kg received one tablet (20 mg artemether plus 120 mg lumefantrine) per dose, those weighing 15-25 kg received two, those of 25-35 kg received three, and those >35 kg received four tablets. In total, six doses were administered at hours 0, 8, 24, 36, 48, and 60. Treatment with both the doses, every day, was directly observed by the study team. No patient had vomiting and, therefore, re-administration of the drug was not required.
Follow-up
All the patients were followed-up on days 1, 2, 3, 7, 14, 21 and 28. On each day, in addition to physical examination, blood smears for malaria parasites and filter paper spot samples for genotyping were obtained.
Laboratory methods
Parasite counts were done on Giemsa-stained thick films and the number of parasites per 200 WBC was counted by light microscopy, by microscopists with 10-15 years of experience. Assuming a WBC count to be 8,000/μl, parasitaemia was calculated and expressed as per μl. A thick smear was regarded as negative on initial review if no parasites were seen in 100 high power fields and 10% of positive and negative slides were cross-checked.
Polymerase chain reaction and nucleotide sequencing Genomic DNA of parasite was isolated from filter paper using QIAamp DNA Blood kit (Qiagen, Valencia, California, USA) according to the manufacturer's instructions and used for a polymerase chain reaction (PCR). To distinguish between recrudescent and new infections PCR method was used to analyse polymorphisms in the merozoite surface protein (MSP) genes, msp-1 and msp-2 in pretreatment and post-treatment isolates following the method described earlier [10] . Table 1 , while the strategy followed for pfcrt analysis was same as described earlier [11] . The PCR products were purified from the agarose gel by using gel extraction Kit (Mdi, Membrane Technology, India). About 50-250 ng of the purified DNA was used for sequencing PCR using ABI Big Dye Terminator Reaction Ready Kit Version 3.1(PE Applied Biosystems, California, USA). The sequencing PCR was performed in a volume of 20 μl with 1 μl of Terminator Ready Reaction Mix (TRR), 3.2 pmol of gene-specific primer. Cycling conditions for the sequencing PCR included 25 cycles of denaturation at 96°C for 10 sec, annealing at 50°C for 5 sec, and extension at 60°C for 4 min. Templates were purified and sequenced on an ABI Prism 310 Genetic Analyzer (PE Applied Biosystems). Regional prevalence of pfmdr1 and pfcrt alleles All the three genotypes of pfmdr1 were present in both Assam (n = 26) and Orissa (n = 32). Single mutant PCR uncorrected and PCR corrected cure rates by per protocol analysis Figure 3 PCR uncorrected and PCR corrected cure rates by per protocol analysis. (Table 4) .
Statistical analysis
Discussion
In India, ACT has been introduced in all Primary health centers (PHCs) of 117 high risk districts and 256 chloroquine resistant PHCs of 48 districts for the treatment of falciparum malaria. The ACT recommended by the National Programme is AS+SP, which is highly effective but available as blister pack and not a fixed dose formulation. AL is the only fixed dose combination that has been approved for marketing recently and there is no data on safety and efficacy of recommended six-dose regimen in India. The present study was carried out to assess the efficacy of AL in India and its correlation with molecular markers. The drug was well tolerated and produced rapid parasite clearance. Majority of patients, viz. 79.2 and 90.1% in Assam and Orissa respectively, were free of parasites within 48 h and cure rates were high at these sites where chloroquine resistance is high.
A case of treatment failure on D7 has been observed for the first time with the six-dose regimen of AL in the study. There is only one earlier report of failure on D9 in a threeyear old child in Comoros [12] . Treatment failure to any drug can be due to true resistance of parasite to drug or inadequate blood levels due to low absorption or altered pharmacokinetics of the drug. Molecular genotyping confirmed recrudescence, which was reiterated by pfcrt haplo- In vivo exposure to AL props up the selection of pfmdr1 86N in new inoculation and is suggested to be associated with tolerance to lumefantrine [4] . However, in this case presence of 86Y ruled out the true drug resistance as the cause of treatment failure. Complete intake of therapeutic dose was ensured by supervised therapy, though blood drug concentration was not determined. The dose was also adequate according to body weight of the child, which was low for his age indicating malnutrition. Artemether component is absorbed rapidly, while absorption of lumefantrine is dependent on co-administration with fat. As fatty food is generally not well tolerated by febrile children, the drug was administered with biscuits and water. Malabsorption syndrome, which could lead to incomplete absorption of drug in the patient, was excluded by negative history of chronic diarrhoea or vomiting. Altered distribution or increased clearance may have led to sub-therapeutic levels of drug leading to treatment failure. As such malnutrition has been shown to cause larger volume of distribution causing lower plasma concentration and hypoalbuminaemia may also lead to increased levels of unbound drug resulting in increased metabolic clearance [2] .
The likelihood of resistance to AL in India is low, since the drug is not included in the National Drug Policy for the treatment of malaria till date. However, recently, marketing permission has been given to few companies. In this scenario, the reappearance of parasites on D7 led us to investigate the possible misuse of the drug. Six brands of AL were available in the town since 2006 and the drug was dispensed without prescription by the local chemists. Discussion with doctors also revealed that drug was being prescribed in various private clinics. This case highlights the need to study the kinetics of drug in malnutrition. In addition, over the counter availability and possible misuse of the drug raises concern of accelerating resistance in near future to one of the valuable ACT.
In addition to clinical outcomes, pre-treatment prevalence of pfmdr1 and pfcrt alleles in Indian P. falciparum isolates was also studied. [11] .
The main limitation of the study is that co-relation of molecular markers with treatment failure was difficult due to very low number of treatment failure cases and drug concentration in this case could not be done.
Considering the prevalence of molecular markers of resistance to sulphadoxine/pyrimethamine (SP) especially in north-eastern states in India [15] , the non-availability of fixed dose combination of AS+SP and the high efficacy of AL, the latter can be considered as a good alternative Lack of correlation of molecular markers for resistance with clinical outcome makes it difficult to monitor and predict resistance to this combination. Efficacy of AL needs to be monitored using in vivo studies and further molecular studies may help in developing markers to predict impending resistance.
Conclusion
Artemether-lumefantrine is safe and effective drug for the treatment of uncomplicated falciparum malaria in India. The efficacy of this ACT needs to be carefully monitored periodically since the treatment failures can occur due to resistance as well as subtherapeutic levels due to inadequate absorption especially if not administered with fat or in malnutrition. As such malnutrition and poor uptake of fat is common in poor tribal population. However, since AL is the only fixed combination available in India till date, it can be a viable alternative to AS+SP for the treatment of uncomplicated falciparum malaria.
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